Structure Therapeutics Inc (NASDAQ: GPCR) is a clinical-stage biotech developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs), a key class of therapeutic targets. Its pipeline includes candidates for obesity, diabetes, and pulmonary fibrosis. Backed by deep expertise and strong early data, Structure offers exposure to breakthrough science in cardiometabolic and fibrotic diseases.
Najnowsze artykuły o akcjach